2023年度黑色素瘤药物治疗研究进展  

Research progress in drug treatment for melanoma in 2023

作　　者：王稼祥 斯璐[1] Wang Jiaxiang;Si Lu(Internal Medicine of Melanoma and Sarcoma,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所、黑色素瘤暨肉瘤内科、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《肿瘤综合治疗电子杂志》2024年第2期54-58,共5页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家自然科学基金项目(82272676);科技部重点研发计划(2023YFC2506404);北京市医院管理中心“登峰”人才计划(DFL20220901);北京微爱公益基金会(JYKY2023-0201208003)。

摘　　要：黑色素瘤是一类高复发、高转移及预后差的恶性肿瘤。近年来,黑色素瘤的发病率呈持续上升的趋势,已成为增长最快的恶性肿瘤之一。黑色素瘤早期主要采用手术治疗,对于不可完全手术切除的黑色素瘤主要依赖免疫治疗、化疗、靶向治疗及放射治疗等手段。层出不穷的新药和新疗法在黑色素瘤患者中应用的疗效和安全性也备受关注。本文旨在回顾总结2023年度黑色素瘤药物治疗领域的研究进展,以期为临床实践提供参考。Melanoma is a class of malignant tumors with high recurrence,high metastasis and poor prognosis.In recent years,the incidence of melanoma has been continuously increasing,and it has become one of the fastest growing malignancies.Earlystage melanoma is primarily treated with surgery,while for melanomas that cannot be completely excised surgically,treatment mainly relies on immunotherapy,chemotherapy,targeted therapy,and radiation therapy.The efficacy and safety of emerging new drugs and new therapies in melanoma patients are also concerned.This paper aims to review and summarize the research progress in thefield of melanoma drug therapy in 2023,in order to provide a reference for clinical practice.

关 键 词：黑色素瘤 免疫治疗 化疗 靶向治疗 

分 类 号：R739.5[医药卫生—肿瘤]